ValuEngine upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a strong sell rating to a sell rating in a report issued on Thursday.
Separately, Zacks Investment Research upgraded Leap Therapeutics from a hold rating to a buy rating and set a $7.00 price target for the company in a report on Wednesday, January 3rd.
Shares of Leap Therapeutics stock opened at $8.54 on Thursday. The company has a market capitalization of $105.50, a PE ratio of -2.43 and a beta of 1.10. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $9.36.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3300732/leap-therapeutics-lptx-lifted-to-sell-at-valuengine.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.